Lantheus Holdings, Inc., a radiopharmaceutical company, has announced an agreement to acquire Evergreen Theragnostics, Inc., this includes a $250 million upfront payment and milestone-based payouts of $752.5 million. The transaction is expected to close in the second half of 2025,
Orbit Discovery, a leader in peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical firm, have announced the extension of their partnership to develop novel targeting peptides. Building on their initial agreement from April 2023, the collaboration focuses on identifying high-affinity
Evergreen Theragnostics, US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today the successful completion of a $26M capital raise. This funding was supported by both existing shareholders and new institutional investors, Petrichor and LIFTT. The raised capital will be
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
